FULC · Fulcrum Therapeutics, Inc.
$3.68
+0.06 (+1.66%)
At close · Jul 21
Market Cap
$246.54M
Shares
66.63M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alex C. Sapir | CEO | $3,251,490 |
| Alan Musso | CFO | $1,807,125 |
| Curtis Oltmans | Chief Legal Officer and Head of External Affairs | $1,482,850 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Patrick Horn | Former Chief Medical Officer | $3,730,273 |
| Curtis Oltmans | Chief Legal Officer and Head of External Affairs | $1,425,240 |
| Alan Musso | CFO | $1,251,760 |
| Alex C. Sapir | CEO | $1,003,300 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Alex C. Sapir | CEO | $6,990,596 |
| Curtis Oltmans | Chief Legal Officer and Head of External Affairs | $2,319,661 |
| Mel Hayes | Executive Vice President, Patient Affairs | $2,192,854 |
| Alan Musso | CFO | $1,879,833 |
| Bryan Stuart | CEO | $1,869,696 |
| Robert J. Gould | CEO | $424,501 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Bryan Stuart | CEO | $3,971,756 |
| Esther Rajavelu | CFO | $3,349,680 |
| Santiago Arroyo | Former Chief Medical Officer | $1,875,318 |
| Robert J. Gould | CEO | $118,342 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Bryan Stuart | CEO | $5,055,104 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert J. Gould | CEO | $3,016,350 |
| Bryan Stuart | COO | $1,774,715 |
| Curtis Oltmans | Chief Legal Officer and Head of External Affairs | $1,357,367 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert J. Gould | CEO | $3,889,353 |
| Owen Wallace | Chief Scientific Officer | $1,559,523 |
| Bryan Stuart | COO | $1,234,960 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Robert J. Gould | CEO | $853,634 |
Key facts
CIK
1680581
CUSIP
359616109
13F (30d)
16 filings
16 filers
Visit website
Investor relations